- Home
- THCH vs CABA Comparison
THCH vs CABA Comparison
Compare THCH & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THCH
- CABA
- Stock Information
- Founded
- THCH 2018
- CABA 2017
- Country
- THCH China
- CABA United States
- Employees
- THCH N/A
- CABA N/A
- Industry
- THCH Blank Checks
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- THCH Finance
- CABA Health Care
- Exchange
- THCH Nasdaq
- CABA Nasdaq
- Market Cap
- THCH 84.8M
- CABA 157.4M
- IPO Year
- THCH N/A
- CABA 2019
- Fundamental
- Price
- THCH $2.96
- CABA $1.69
- Analyst Decision
- THCH
- CABA Strong Buy
- Analyst Count
- THCH 0
- CABA 7
- Target Price
- THCH N/A
- CABA $14.43
- AVG Volume (30 Days)
- THCH 17.2K
- CABA 2.2M
- Earning Date
- THCH 08-28-2025
- CABA 08-07-2025
- Dividend Yield
- THCH N/A
- CABA N/A
- EPS Growth
- THCH N/A
- CABA N/A
- EPS
- THCH N/A
- CABA N/A
- Revenue
- THCH $187,384,526.00
- CABA N/A
- Revenue This Year
- THCH N/A
- CABA N/A
- Revenue Next Year
- THCH N/A
- CABA N/A
- P/E Ratio
- THCH N/A
- CABA N/A
- Revenue Growth
- THCH N/A
- CABA N/A
- 52 Week Low
- THCH $2.15
- CABA $0.99
- 52 Week High
- THCH $5.15
- CABA $8.44
- Technical
- Relative Strength Index (RSI)
- THCH 61.84
- CABA 48.60
- Support Level
- THCH $2.86
- CABA $1.43
- Resistance Level
- THCH $2.99
- CABA $1.78
- Average True Range (ATR)
- THCH 0.10
- CABA 0.12
- MACD
- THCH 0.01
- CABA 0.00
- Stochastic Oscillator
- THCH 100.00
- CABA 65.00
About THCH TH International Limited Ordinary shares
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under single reportable segment, Tim Hortons. The company's revenue is derived from its operations in the PRC.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.